Cady 1998.

Methods	Multicentre, randomised, double‐blind, placebo‐controlled, parallel‐group. Single dose to treat single attack. Medication administered when migraine headache of moderate or severe intensity occurred within the first 4 h of a minimum 8 h work shift Assessments at 1 and 2 h after dosing Rescue medication (with the exception of ergotamine‐containing medications or sumatriptan) available after 2 h for intolerable pain Second dose of study medication available to treat recurrence in the workplace, provided no use of rescue medication had occurred
Participants	Aged 18 years or over, meeting IHS criteria for migraine (1988) with or without aura. At least 1‐year history of migraine (untreated severity ≥ moderate) with an average of 1 to 6 attacks per month. Participants had to have treated at last 1 disabling migraine in the workplace in the past 60 days, and had to be working 8‐hour (minimum) shifts at their jobs No monoamine oxidase inhibitors within 2 weeks of screening. No ergotamine‐containing medications or sumatriptan within 24 h, and no analgesics, antiemetics, or other acute migraine medications within 6 h of taking study medication. Participants were excluded if they had previously used sumatriptan (any formulation) N = 135 (132 for efficacy) M 20, F 112 (85%) Mean age 40 years Without aura 69%
Interventions	Sumatriptan 6 mg, n = 67 Placebo, n = 68 (65 for efficacy)
Outcomes	Use of rescue medication Adverse events Withdrawals
Notes	Oxford Quality Score: R1, DB2, W1. Total = 4.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not reported
Allocation concealment (selection bias)	Unclear risk	Not reported
Blinding (performance bias and detection bias) All outcomes	Low risk	Matching placebo
Study size	Unclear risk	Treatment groups 50 to 200 participants